Treatment of diabetes and heart failure: joint forces

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial

(2016) David Fitchett et al.   EUROPEAN HEART JOURNAL

Screening for dysglycaemia in patients with coronary artery disease as reflected by fasting glucose, oral glucose tolerance test, and HbA1c: a report from EUROASPIRE IV—a survey from the European Society of Cardiology

(2015) Viveca Gyberg et al.   EUROPEAN HEART JOURNAL

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular mechanisms of diabetic cardiomyopathy

(2014) Heiko Bugger et al.   DIABETOLOGIA

Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored

(2014) John J V McMurray et al.   Lancet Diabetes & Endocrinology

ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

(2013)   EUROPEAN HEART JOURNAL

Is the prognosis in patients with diabetes and heart failure a matter of unsatisfactory management? An observational study from the Swedish Heart Failure Registry

(2013) Isabelle Johansson et al.   EUROPEAN JOURNAL OF HEART FAILURE

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

(2013) Benjamin M. Scirica et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association Between Extracellular Matrix Expansion Quantified by Cardiovascular Magnetic Resonance and Short-Term Mortality

(2012) Timothy C. Wong et al.   CIRCULATION

Diabetes: a driver for heart failure

(2011) A. A. Voors et al.   HEART

Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Diabetic cardiomyopathy – a distinct disease?

(2009) Kaivan Khavandi et al.   BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM